Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ABCSG TR Spotlight: Validation of an Artificial Intelligence-based Prognostic Assay in ER+/HER2- Breast Cancer

NCT07541703 is registered in ClinicalTrials.gov with Spotlight Medical as lead sponsor.

NCT NCT07541703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07541703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ABCSG TR Spotlight: Validation of an Artificial Intelligence-based Prognostic Assay in ER+/HER2- Breast Cancer
Lead sponsor
Spotlight Medical
Phase
Observational
Overall status
Active, not recruiting
Start date
April 1, 2026
Completion date
March 31, 2028
Enrollment
2,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early breast cancer, er-positive her2-negative breast cancer